Advertisement
Advertisement
SUPN
Supernus Pharmaceuticals, Inc.
51.53
USDSponsored
-0.75
-1.43%
May 08, 16:00 UTC -4
Closed
After-Market
51.59
+0.06
+0.12%
SUPN Earnings Reports
Positive Surprise Ratio
SUPN beat 31 of 42 last estimates.
74%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$215.24M
/$0.50
Implied change from Q1 26 (Revenue/ EPS)
+3.63%
/-15.25%
Implied change from Q2 25 (Revenue/ EPS)
+30.09%
/-44.44%
Supernus Pharmaceuticals, Inc. earnings per share and revenue
On May 05, 2026, SUPN reported earnings of 0.59 USD per share (EPS) for Q1 26, beating the estimate of 0.30 USD, resulting in a 94.40% surprise. Revenue reached 207.71 million, compared to an expected 196.78 million, with a 5.56% difference. The market reacted with a +4.59% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of 0.50 USD, with revenue projected to reach 215.24 million USD, implying an decrease of -15.25% EPS, and increase of 3.63% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bausch Health Companies Inc
Report Date
Apr 29, 2026 For Q1 26
Estimate
$0.69
Actual
$0.78
Surprise
+12.33%
Teva Pharmaceutical Industries Limited - ADR
Report Date
Apr 29, 2026 For Q1 26
Estimate
$0.48
Actual
$0.53
Surprise
+8.78%
BridgeBio Pharma, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.69
Actual
-$0.84
Surprise
-21.37%
Taysha Gene Therapies, Inc. Common Stock
Report Date
May 06, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.12
Surprise
-20.48%
Amphastar Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.71
Actual
$0.42
Surprise
-41.59%
Personalis, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-5.42%
FAQ
What were Supernus Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Supernus Pharmaceuticals, Inc. reported EPS of $0.59, beating estimates by 94.4%, and revenue of $207.71M, 5.56% above expectations.
How did the market react to Supernus Pharmaceuticals, Inc.'s Q1 2026 earnings?
The stock price moved up 4.59%, changed from $49.19 before the earnings release to $51.45 the day after.
When is Supernus Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Supernus Pharmaceuticals, Inc.'s next earnings report?
Based on 6
analysts, Supernus Pharmaceuticals, Inc. is expected to report EPS of $0.50 and revenue of $215.24M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement